02.10.2017 • News

Asahi Kasei and Bluestar Studying mPPE

(c) mmmx/Shutterstock
(c) mmmx/Shutterstock

Japan’s Asahi Kasei and China’s Bluestar, a ChemChina subsidiary, have agreed to study the economics of building production facilities for producing a modified polyphenylene ether (mPPE) in China.

The facilities would include the intermediates 2,6-xylenol and polyphenylene ether (PPE). Following completion of detailed feasibility studies, the companies plan to make a final investment decision by March 2018.

The plans will be realized by a joint venture agreed in February of this year and will leverage Bluestar’s technology for 2,6-xylenol and PPE in combination with Asahi Kasei’s mPPE compounding technology and applications development capability.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

Interview

Driving Transformation
Interconnected Global Chemicals Logistics

Driving Transformation

DP World is reshaping global chemical supply chains. Christene Smith of CHEManager interviews Markus Kanis, Global SVP Chemicals, on the company’s roadmap, new technologies, and the evolving demands of global trade.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.